NeuroPace (NPCE) EPS (Diluted) Growth (1y) (2021 - 2026)
NeuroPace (NPCE) EPS (Diluted) Growth (1y) (2021 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.74 Bn | 176.45 Bn | 6.27 Bn | -18.71% |
| 2 | Stryker | 128.89 Bn | 126.01 Bn | 3.81 Bn | 13.88% |
| 3 | Medtronic | 108.48 Bn | 99.26 Bn | 6.41 Bn | 18.72% |
| 4 | Boston Scientific | 68.51 Bn | 67.05 Bn | 3.61 Bn | 98.71% |
| 5 | Edwards Lifesciences | 48.32 Bn | 44.65 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.41 Bn | 27.29 Bn | 750.30 Mn | 95.96% |
| 7 | GE HealthCare Technologies | 28.23 Bn | 25.95 Bn | 1.98 Bn | -29.80% |
| 8 | Smith & Nephew | 26.90 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.47 Bn | 21.35 Bn | 2.07 Bn | 114.19% |
| 10 | NeuroPace | 518.90 Mn | 464.92 Mn | 18.05 Mn | -212.94% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -212.94% |
| Dec 31, 2025 | 33.72% |
| Sep 30, 2025 | 22.13% |
| Jun 30, 2025 | -151.46% |
| Mar 31, 2025 | 34.70% |
| Dec 31, 2024 | 28.60% |
| Sep 30, 2024 | 31.81% |
| Jun 30, 2024 | 26.78% |
| Mar 31, 2024 | 16.28% |
| Dec 31, 2023 | 44.40% |
| Sep 30, 2023 | 40.02% |
| Jun 30, 2023 | 29.44% |
| Mar 31, 2023 | 19.21% |
| Dec 31, 2022 | 35.40% |
| Sep 30, 2022 | -43.52% |
| Jun 30, 2022 | -41.58% |
| Mar 31, 2022 | 97.77% |
| Dec 31, 2021 | 95.48% |
| Sep 30, 2021 | 98.32% |
| Jun 30, 2021 | 98.99% |